Stock Taper 
| DATE | TYPE | RATIO |
|---|---|---|
| 2024-02-29 | Reverse | 1:10 |
Celularity Inc. is a biotech company developing off-the-shelf placental-derived cell therapies for cancer, immune, and infectious diseases, with programs in clinical and preclinical stages, and operates in biobanking and wound care markets.
Celularity's flagship regenerative medicine product is a human amniotic membrane allograft used in wound care and surgery, supporting tissue regeneration and recently benefiting from ongoing Medicare coverage.
Celularity Inc. announced the peer-reviewed publication of its Phase 2 clinical trial results for PDA-002, a human placenta-derived cell therapy for diabetic foot ulcers complicated by peripheral artery disease. The positive safety and efficacy data, published in the International Wound Journal, demonstrated improved wound closure rates and a favorable safety profile, leading to a significant increase in the company's stock price and renewed investor interest in its regenerative medicine platform.
In a pivotal strategic move, Celularity retired its entire senior secured debt of $41.6 million by monetizing its intellectual property assets while retaining exclusive use through a license agreement. [1, 15] Concurrently, the company reorganized its internal structure, establishing four distinct operating subsidiaries for its core business units to enhance focus and operational efficiency. [1, 14]
Celularity highlights Fontaine Vitale's planned Q1 2027 opening in Bali, creating potential new revenue opportunities in Asia-Pacific regenerative medicine
Overall rating: C
| PEER | PRICE | |
|---|---|---|
 PYPD | $4.94 | COMPARE |
 ANVS | $1.22 | COMPARE |
 TPST | $0.80 | COMPARE |
 RVPH | $0.51 | COMPARE |
